Gene Therapy(FT-003) for Wet AMD

NCTID	NCT06492863 (View at clinicaltrials.gov)
Description	The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of disposable vitreous injection of FT-003 in subjects with neovascular age-related Macular Degeneration (nAMD). The study was divided into two phases, Phase 1 dose escalation and Phase II dose expansion. (Show More)
Development Status	Active
Indication	Neovascular (Wet) Age-Related Macular Degeneration (nAMD)
Disease Ontology Term	DOID:10871
Compound Name	FT-003
Sponsor	Frontera Therapeutics
Funder Type	Industry
Recruitment Status	Recruiting
Enrollment Count	78
Results Posted	Not Available

Target Gene/Variant	Aflibercept
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	Genetic delivery of therapeutic protein
Route of Administration	Intravitreal
Drug Product Type	Viral vector
Target Tissue/Cell
Delivery System	Viral transduction
Vector Type	AAV2.7m8
Editor Type	none
Dose 1	Undisclosed low dose
Dose 2	Undisclosed medium dose
Dose 3	Undisclosed high dose
Dose 4
Dose 5

No.of Trial Sites	1
Locations	China

Has US IND	False
FDA Designations
Recent Updates	FDA clearance for Phase 2 trial received 11/11/24